Illumina Inc. faces yet another setback from regulatory officials regarding the company’s $8 billion acquisition of GRAIL Inc. as the European Commission provided an update.
Martin Shkreli received his second lifetime ban from the pharmaceutical industry. One month after U.S. District Court Judge Denise Cotes banned the “Pharma Bro” from future involvement in the industry, a second judge handed down a similar order and ordered him to pay a $1.39 million fine.
A U.S. judge on January 14 barred Martin Shkreli from the pharmaceutical industry for life and ordered him to pay $64.6 million after he famously raised the price of the drug Daraprim and fought to block generic competitors.
The Federal Trade Commission (FTC) requested additional information about AbbVie company Allergan Aesthetics’ acquisition of Soliton, according to a filing by Soliton with the U.S. Securities and Exchange Commission (SEC) on August 6.
AstraZeneca’s $39 billion acquisition of Alexion is being investigated by the UK’s Competition and Markets Authority (CMA) to determine if the deal is anti-competitive.
The U.S. Federal Trade Commission (FTC) formed a multinational working group to evaluate pharmaceutical mergers.
The U.S. Federal Trade Commission filed a lawsuit against Endo Pharmaceuticals and Impax Laboratories that alleges a 2017 agreement eliminated competition between the companies for the pain medicine oxymorphone ER.
The U.S. Federal Trade Commission gave the green light to the $63 billion merger of AbbVie and Allergan.
Generic drugmaker Aurobindo Pharma called off the company’s $1 billion acquisition plans for multiple assets owned by Sandoz after failing to secure approval from the Federal Trade Commission.
AbbVie and Allergan are closer to completing the $63 billion combination of the two companies after entering into a consent decree agreement with the Federal Trade Commission that commits them to a previously announced divestiture of products ahead of the merger.